循環器ジャーナル70巻2号

2022年04月発行

特集 循環器薬の使い方—使い分け，モニタリング，導入・中止のタイミング Ⅱ章　心不全

ミネラルコルチコイド受容体阻害薬（MRA）をどう使う？

著者： 名越智古¹

所属機関： ¹東京慈恵会医科大学内科学講座循環器内科

ページ範囲：P.225 - P.231

Point
・MRAは心不全治療の主要4薬剤の一つである．
・MRはアルドステロン以外のリガンドやリガンド非依存性にも活性化されうる．
・MRは高食塩環境下において，様々な病的作用を引き起こす．

参考文献

1）Lam CSP, Butler J : Victims of Success in Failure. Circulation 142 : 1129-1131, 2020

2）Mizuno Y, Yoshimura M, Yasue H, et al : Aldosterone production is activated in failing ventricle in humans. Circulation 103 : 72-77, 2001

3）Yoshimura M, Nakamura S, Ito T, et al : Expression of aldosterone synthase gene in failing human heart : quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 87 : 3936-3940, 2002

4）Singh VP, Le B, Khode R, et al : Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 57 : 3297-3306, 2008

5）Fujisaki M, Nagoshi T, Nishikawa T, et al : Rapid Induction of Aldosterone Synthesis in Cultured Neonatal Rat Cardiomyocytes under High Glucose Conditions. Biomed Res Int 2013 : 161396, 2013

6）Pitt B, Pedro Ferreira J, Zannad F : Mineralocorticoid receptor antagonists in patients with heart failure : current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother 3 : 48-57, 2017

7）Nagase M, Yoshida S, Shibata S, et al : Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome : possible contribution of fat-derived factors. J Am Soc Nephrol 17 : 3438-3446, 2006

8）Mihailidou AS, Loan Le TY, Mardini M, et al : Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54 : 1306-1312, 2009

9）Young MJ, Clyne CD : Mineralocorticoid receptor actions in cardiovascular development and disease. Essays Biochem 65 : 901-911, 2021

10）Shibata S, Nagase M, Yoshida S, et al : Modification of mineralocorticoid receptor function by Rac1 GTPase : implication in proteinuric kidney disease. Nat Med 14 : 1370-1376, 2008

11）Shibata H, Itoh H : Mineralocorticoid receptor-associated hypertension and its organ damage : clinical relevance for resistant hypertension. Am J Hypertens 25 : 514-523, 2012

12）Ohtani T, Ohta M, Yamamoto K, et al : Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure : Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 292 : R946-R954, 2007

13）Matsui H, Ando K, Kawarazaki H, et al : Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 52 : 287-294, 2008

14）Ayuzawa N, Nagase M, Ueda K, et al : Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury. Hypertension 67 : 99-106, 2016

15）De Giusti VC, Orlowski A, Ciancio MC, et al : Aldosterone stimulates the cardiac sodium/bicarbonate cotransporter via activation of the g protein-coupled receptor gpr30. J Mol Cell Cardiol 89 : 260-267, 2015

16）Ruhs S, Nolze A, Hubschmann R, et al : 30 YEARS OF THE MINERALOCORTICOID RECEPTOR : Nongenomic effects via the mineralocorticoid receptor. J Endocrinol 234 : T107-T124, 2017

17）Hermidorff MM, de Assis LV, Isoldi MC : Genomic and rapid effects of aldosterone : what we know and do not know thus far. Heart Fail Rev 22 : 65-89, 2017

18）Cooper SA, Whaley-Connell A, Habibi J, et al : Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293 : H2009-H2023, 2007

19）Nagoshi T, Yoshimura M, Rosano GM, et al : Optimization of Cardiac Metabolism in Heart Failure. Curr Pharm Des 17 : 3846-3853, 2011

20）Rocha R, Rudolph AE, Frierdich GE, et al : Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 : H1802-H1810, 2002

21）Favre J, Gao J, Zhang AD, et al : Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 300 : H2035-H2043, 2011

22）Jaisser F, Swynghedauw B, Delcayre C : The mineralocorticoid receptor in heart : different effects in different cells. Hypertension 57 : 679-680, 2011

23）Pitt B, Zannad F, Remme WJ, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999

24）Pitt B, Remme W, Zannad F, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003

25）Zannad F, McMurray JJ, Krum H, et al : Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 : 11-21, 2011

26）Pitt B, Pfeffer MA, Assmann SF, et al : Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 : 1383-1392, 2014

27）Pitt B, Filippatos G, Agarwal R, et al : Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 385 : 2252-2263, 2021

28）Tsutsui H, Ito H, Kitakaze M, et al : Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure（J-EMPHASIS-HF）. Circ J 82 : 148-158, 2017

29）Tsutsui H, Isobe M, Ito H, et al : JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure-Digest Version. Circ J 83 : 2084-2184, 2019

30）Tsutsui H, Ide T, Ito H, et al : JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. J Card Fail 27 : 1404-1444, 2021